Johnson & Johnson begins U.S. push into soft-tissue robotic surgery after FDA De Novo nod for OTTAVA

Johnson & Johnson has formally moved into the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system, according to a market report published Tuesday.

De Novo is a specific FDA pathway used when a device has no legally marketed equivalent, allowing the agency to grant authorization based on safety and effectiveness for that new category of technology. In this case, the approval positions OTTAVA to compete in a market that has been largely shaped by Intuitive Surgical’s da Vinci platform and related offerings.

The market report frames the new authorization as a direct competitive challenge to Intuitive Surgical, which is represented by the ticker ISRG. Intuitive Surgical has long been the main U.S. supplier for robotic-assisted procedures, and its installed base has helped drive recurring demand through system placements, procedure volumes, and service and instrument revenue streams.

Johnson & Johnson’s entry through OTTAVA is noteworthy not only for who it challenges, but also because it indicates that a major diversified healthcare company is still willing to spend and seek regulatory clearance in a surgical technology category that requires substantial clinical evidence, surgeon training, and long-term support.

For investors and customers, the practical question will be how quickly OTTAVA can translate FDA authorization into real-world use. While De Novo approval indicates FDA clearance for the intended device category, widespread adoption typically depends on hospital evaluations, credentialing and training for surgeons and staff, and the availability and pricing of the system’s consumables and service coverage.

Still, the report does not provide additional operational detail, such as which specific soft-tissue indications OTTAVA is cleared to address, how the company expects to deploy the system commercially, or what timeline it is using for broader rollout. Without those specifics, it is unclear how fast Johnson & Johnson can convert the regulatory milestone into meaningful procedure volumes or revenue.

In the meantime, the timing matters for the competitive landscape. Intuitive Surgical’s business model is closely tied to the growth of robotic procedures, particularly as health systems weigh the clinical workflow and economics of robotic-assisted surgery against conventional approaches.

What to watch next is whether Johnson & Johnson follows the FDA authorization with clearer commercial disclosures, such as deployment plans, payer and hospital adoption indicates, and any updates on how the OTTAVA system will be supported post-sale. The next milestones will likely be incremental: additional regulatory data, early site announcements, and evidence of growing procedure activity.